Development of a Library of Disulfide Bond-Containing Cationic Lipids for mRNA Delivery
Lipid nanoparticles (LNPs) are the commonly used delivery tools for messenger RNA (mRNA) therapy and play an indispensable role in the success of COVID-19 mRNA vaccines. Ionizable cationic lipids are the most important component in LNPs. Herein, we developed a series of new ionizable lipids featuring bioreducible disulfide bonds, and constructed a library of lipids derived from dimercaprol. LNPs prepared from these ionizable lipids could be stored at 4 °C for a long term and are non-toxic toward HepG2 and 293T cells. In vivo experiments demonstrated that the best C4S18A formulations, which embody linoleoyl tails, show strong firefly luciferase (Fluc) mRNA expression in the liver and spleen via intravenous (IV) injection, or at the local injection site via intramuscular injection (IM). The newly designed ionizable lipids can be potentially safe and high-efficiency nanomaterials for mRNA therapy..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Pharmaceutics - 15(2023), 2, p 477 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhigao Shen [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Disulfide bond |
|---|
| doi: |
10.3390/pharmaceutics15020477 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ080002463 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ080002463 | ||
| 003 | DE-627 | ||
| 005 | 20240413061721.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230310s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/pharmaceutics15020477 |2 doi | |
| 035 | |a (DE-627)DOAJ080002463 | ||
| 035 | |a (DE-599)DOAJ51e6311a37594d8fb26682b82fc8ee35 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RS1-441 | |
| 100 | 0 | |a Zhigao Shen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development of a Library of Disulfide Bond-Containing Cationic Lipids for mRNA Delivery |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Lipid nanoparticles (LNPs) are the commonly used delivery tools for messenger RNA (mRNA) therapy and play an indispensable role in the success of COVID-19 mRNA vaccines. Ionizable cationic lipids are the most important component in LNPs. Herein, we developed a series of new ionizable lipids featuring bioreducible disulfide bonds, and constructed a library of lipids derived from dimercaprol. LNPs prepared from these ionizable lipids could be stored at 4 °C for a long term and are non-toxic toward HepG2 and 293T cells. In vivo experiments demonstrated that the best C4S18A formulations, which embody linoleoyl tails, show strong firefly luciferase (Fluc) mRNA expression in the liver and spleen via intravenous (IV) injection, or at the local injection site via intramuscular injection (IM). The newly designed ionizable lipids can be potentially safe and high-efficiency nanomaterials for mRNA therapy. | ||
| 650 | 4 | |a lipid nanoparticles | |
| 650 | 4 | |a mRNA delivery | |
| 650 | 4 | |a disulfide bond | |
| 653 | 0 | |a Pharmacy and materia medica | |
| 700 | 0 | |a Cong Liu |e verfasserin |4 aut | |
| 700 | 0 | |a Ziqian Wang |e verfasserin |4 aut | |
| 700 | 0 | |a Fengfei Xie |e verfasserin |4 aut | |
| 700 | 0 | |a Xingwu Liu |e verfasserin |4 aut | |
| 700 | 0 | |a Lingkai Dong |e verfasserin |4 aut | |
| 700 | 0 | |a Xuehua Pan |e verfasserin |4 aut | |
| 700 | 0 | |a Chen Zeng |e verfasserin |4 aut | |
| 700 | 0 | |a Peng George Wang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Pharmaceutics |d MDPI AG, 2010 |g 15(2023), 2, p 477 |w (DE-627)DOAJ000114154 |x 19994923 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:2, p 477 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/pharmaceutics15020477 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/51e6311a37594d8fb26682b82fc8ee35 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.mdpi.com/1999-4923/15/2/477 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1999-4923 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 2, p 477 | ||